Proteasome inhibition-induced p38 MAPK/ERK signaling regulates autophagy and apoptosis through the dual phosphorylation of glycogen synthase kinase 3β

Biochem Biophys Res Commun. 2012 Feb 24;418(4):759-64. doi: 10.1016/j.bbrc.2012.01.095. Epub 2012 Jan 28.

Abstract

Proteasome inhibition is a promising approach for cancer treatment; however, the underlying mechanisms involved have not been fully elucidated. Here, we show that proteasome inhibition-induced p38 mitogen-activated protein kinase regulates autophagy and apoptosis by modulating the phosphorylation status of glycogen synthase kinase 3β (GSK3β) and 70kDa ribosomal S6 kinase (p70S6K). The treatment of MDA-MB-231 cells with MG132 induced endoplasmic reticulum stress through the induction of ATF6a, PERK phosphorylation, and CHOP, and apoptosis through the cleavage of Bax and procaspase-3. MG132 caused the phosphorylation of GSK3β at Ser(9) and, to a lesser extent, Thr(390), the dephosphorylation of p70S6K at Thr(389), and the phosphorylation of p70S6K at Thr(421) and Ser(424). The specific p38 inhibitor SB203080 reduced the p-GSK3β(Ser9) and autophagy through the phosphorylation of p70S6K(Thr389); however, it augmented the levels of p-ERK, p-GSK3β(Thr390), and p-70S6K(Thr421/Ser424) induced by MG132, and increased apoptotic cell death. The GSK inhibitor SB216763, but not lithium, inhibited the MG132-induced phosphorylation of p38, and the downstream signaling pathway was consistent with that in SB203580-treated cells. Taken together, our data show that proteasome inhibition regulates p38/GSK(Ser9)/p70S6K(Thr380) and ERK/GSK3β(Thr390)/p70S6K(Thr421/Ser424) kinase signaling, which is involved in cell survival and cell death.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • Autophagy / drug effects*
  • Breast Neoplasms / enzymology*
  • Cell Cycle Checkpoints
  • Cell Line, Tumor
  • Cysteine Proteinase Inhibitors / pharmacology*
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Female
  • Glycogen Synthase Kinase 3 / metabolism*
  • Glycogen Synthase Kinase 3 beta
  • Humans
  • Leupeptins / pharmacology*
  • MAP Kinase Signaling System / drug effects
  • Phosphorylation
  • Proteasome Inhibitors*
  • Ribosomal Protein S6 Kinases, 70-kDa / metabolism
  • p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

  • Cysteine Proteinase Inhibitors
  • Leupeptins
  • Proteasome Inhibitors
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Ribosomal Protein S6 Kinases, 70-kDa
  • Extracellular Signal-Regulated MAP Kinases
  • p38 Mitogen-Activated Protein Kinases
  • Glycogen Synthase Kinase 3
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde